Recent submissions
Now showing items 1-20 of 4595
-
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
(ELSEVIER SCIENCE INC, 2023-05-01)BACKGROUND: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, ... -
Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial.
(BMC, 2023-09-19)BACKGROUND: Bladder and urinary tract cancers account for approximately 21,000 new diagnoses and 5,000 deaths annually in the UK. Approximately 90% are transitional cell carcinomas where advanced disease is treated with ... -
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
(SPRINGERNATURE, 2023-11-23)BACKGROUND: Active surveillance after orchiectomy is the preferred management in clinical stage I (CSI) germ-cell tumours (GCT) associated with a 15 to 30% relapse rate. PATIENTS AND METHODS: In the IGCCCG Update database, ... -
The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease.
(SPRINGER, 2017-04-01)Diffuse intrinsic pontine glioma (DIPG), a rare, often fatal childhood brain tumor, remains a major therapeutic challenge. In 2012, investigators, funded by the DIPG Collaborative (a philanthropic partnership among 29 ... -
Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study.
(SPRINGER, 2020-02-01)Pineoblastomas (PBs) are rare, aggressive pediatric brain tumors of the pineal gland with modest overall survival despite intensive therapy. We sought to define the clinical and molecular spectra of PB to inform new treatment ... -
The Long Non-Coding RNA H19 Drives the Proliferation of Diffuse Intrinsic Pontine Glioma with H3K27 Mutation.
(MDPI, 2021-08-25)Diffuse intrinsic pontine glioma (DIPG) is an incurable paediatric malignancy. Identifying the molecular drivers of DIPG progression is of the utmost importance. Long non-coding RNAs (lncRNAs) represent a large family of ... -
Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas.
(AMER ASSOC ADVANCEMENT SCIENCE, 2021-10-13)High-grade gliomas with arginine or valine substitutions of the histone H3.3 glycine-34 residue (H3.3G34R/V) carry a dismal prognosis, and current treatments, including radiotherapy and chemotherapy, are not curative. ... -
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition.
(AMER ASSOC CANCER RESEARCH, 2022-03-01)UNLABELLED: The survival of children with diffuse intrinsic pontine glioma (DIPG) remains dismal, with new treatments desperately needed. In a prospective biopsy-stratified clinical trial, we combined detailed molecular ... -
Inter and intra-tumor heterogeneity of paediatric type diffuse high-grade gliomas revealed by single-cell mass cytometry.
(FRONTIERS MEDIA SA, 2022-12-08)Paediatric-type diffuse high-grade gliomas (PDHGG) are aggressive tumors affecting children and young adults, with no effective treatment. These highly heterogeneous malignancies arise in different sites of the Central ... -
Getting our ducks in a row: The need for data utility comparisons of healthcare systems data for clinical trials.
(Elsevier BV, 2024-03-25)BACKGROUND: Better use of healthcare systems data, collected as part of interactions between patients and the healthcare system, could transform planning and conduct of randomised controlled trials. Multiple challenges to ... -
Characterisation of a cyclic peptide that binds to the RAS binding domain of phosphoinositide 3-kinase p110 alpha
(NATURE PORTFOLIO, 2023-02-02)<jats:title>Abstract</jats:title><jats:p>P110α is a member of the phosphoinositide 3-kinase (PI3K) enzyme family that functions downstream of RAS. RAS proteins contribute to the activation of p110α by interacting directly ... -
Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public representatives.
(BMJ, 2024-03-19)OBJECTIVES: To explore the importance of, and barriers to achieving, diversity in early-phase clinical trials. DESIGN: Qualitative interviews analysed using thematic analysis. SETTING AND PARTICIPANTS: Five professionals ... -
Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival.
(Elsevier BV, 2024-03-07)BACKGROUND: Prostate cancer (PrCa) is a substantial cause of mortality among men globally. Rare germline mutations in BRCA2 have been validated robustly as increasing risk of aggressive forms with a poorer prognosis; ... -
FUME-TCRseq enables sensitive and accurate sequencing of the T-cell receptor from limited input of degraded RNA.
(American Association for Cancer Research, 2024-03-14)Genomic analysis of the T-cell receptor (TCR) reveals the strength, breadth, and clonal dynamics of the adaptive immune response to pathogens or cancer. The diversity of the TCR repertoire, however, means that sequencing ... -
Genomic evolution shapes prostate cancer disease type.
(Elsevier BV, 2024-03-13)The development of cancer is an evolutionary process involving the sequential acquisition of genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly proliferate and eventually invade ... -
On the Co-Dependence of Cell Morphology and Biochemistry in Cancer
(Institute of Cancer Research (University Of London), 2024-03-25)Shape and form are fundamental to biology. Acting at all scales, from the organismal to the molecular, morphology defines the functionality of biological structures. It is obvious that chemical events in the cell, influence ... -
Targeting Endo180 with an antibody-drug conjugate for cancer treatment
(Institute of Cancer Research (University Of London), 2024-03-22)Antibody-drug conjugates (ADCs) are formed of an antibody attached to a cytotoxic drug via a linker which is cleaved upon internalisation of the ADC into the cell. This allows very toxic drugs to be directed to specific ... -
Molecular subtypes of cancer-associated fibroblasts and their regulation of the tumour microenvironment in pancreatic ductal adenocarcinoma.
(Institute of Cancer Research (University Of London), 2024-03-21)Pancreatic Ductal Adenocarcinoma (PDAC) remains a leading cause of cancer-related deaths, with a 5-year survival rate of less than 10 % in Western countries. Transcriptomic analysis of PDAC in the last decade has unearthed ... -
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting.
(NATURE PORTFOLIO, 2023-12-15)Rhabdomyosarcomas (RMS) are pediatric mesenchymal-derived malignancies encompassing PAX3/7-FOXO1 Fusion Positive (FP)-RMS, and Fusion Negative (FN)-RMS with frequent RAS pathway mutations. RMS express the master myogenic ... -
Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
(BMC, 2023-12-15)BACKGROUND: Bone biopsies in metastatic castrate-resistant prostate cancer (mCRPC) patients can be challenging. This study's objective was to prospectively validate a multiparametric bone MRI (mpBMRI) algorithm to facilitate ...